Web Results


Treatment Guidelines Title Format; Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 MMWR Recomm Rep 2020; 69(No. RR-1): 1-11. PDF pdf icon (337 KB) Treatment of Drug-Resistant Tuberculosis American Journal of Respiratory and Critical Care Medicine ...


CDC and other federal agencies provide recommendations for the prevention, treatment, and management of tuberculosis (TB). This information is intended to serve as guidance for clinicians and public health professionals, as well as for those who may be at risk. CDC TB Guidelines CDC Resources & MMWR Recommendations and Reports Guides and Toolkits


If person is exposed to known multidrug-resistant (MDR) TB: Positive TST or IGRA result → Consult an expert in the treatment of MDR TB; In general, TST or IGRA-positive contacts who can provide written documentation of prior adequate treatment for LTBI do not need to be retreated.


The guidelines, published in the CDC's Dec. 16 Morbidity and Mortality Weekly Report, affirm that QuantiFERON-TB GOLD can be administered in place of the 100-year-old TST, which despite widespread use can be unreliable because of false-positive and false-negative results.


Consultation with a TB expert is advised if the known source of TB infection has drug-resistant TB. Read Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 to learn more about treatment regimens for latent TB infection.


CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005; 54 (No. RR-17). CDC. Mantoux Tuberculin Skin Test: Training Materials Kit (2003). CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection pdf icon. MMWR 2000; 49 (No. RR-6).


Links with this icon indicate that you are leaving the CDC website.. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.


CDC/ATS/IDSA have published guidelines on treatment for drug-susceptible TB disease. PREVENTION Travelers should avoid exposure to people with TB disease in crowded and enclosed environments (such as health care facilities, correctional facilities, or homeless shelters).


A positive TB skin test or TB blood test only tells that a person has been infected with TB bacteria. It does not tell whether the person has latent TB infection (LTBI) or has progressed to TB disease. Other tests, such as a chest x-ray and a sample of sputum, are needed to see whether the person has TB disease. Diagnosis


Treatment of latent TB infection should start after excluding the possibility of TB disease. Groups Who Should be Given High Priority for Latent TB Infection Treatment include: People with a positive TB blood test (interferon-gamma release assay or IGRA). People with a tuberculin skin test (TST) reaction of 5 or more millimeters who are: